Evolus (NASDAQ:EOLS) Given “Buy” Rating at BTIG Research

BTIG Research reissued their buy rating on shares of Evolus (NASDAQ:EOLS) in a report published on Wednesday,Benzinga reports. The brokerage currently has a $13.00 price objective on the stock.

Several other equities research analysts have also recently commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Evolus in a research report on Monday, December 22nd. Mizuho set a $15.00 price objective on Evolus in a research report on Wednesday, February 4th. Wall Street Zen upgraded Evolus from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Stifel Nicolaus lowered their target price on Evolus from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Tuesday, January 13th. Finally, HC Wainwright dropped their price target on Evolus from $20.00 to $13.00 and set a “buy” rating on the stock in a research report on Tuesday, February 3rd. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Evolus currently has an average rating of “Moderate Buy” and an average target price of $16.00.

Evolus Stock Performance

Shares of EOLS stock opened at $5.59 on Wednesday. Evolus has a fifty-two week low of $4.09 and a fifty-two week high of $14.60. The firm has a market cap of $362.34 million, a P/E ratio of -6.90 and a beta of 1.02. The business’s 50 day moving average price is $5.09 and its 200-day moving average price is $6.24.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported $0.00 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.09). The company had revenue of $90.30 million during the quarter, compared to the consensus estimate of $89.58 million. As a group, equities analysts predict that Evolus will post -0.61 EPS for the current year.

Insider Activity at Evolus

In other Evolus news, insider David Moatazedi sold 10,539 shares of Evolus stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $7.15, for a total transaction of $75,353.85. Following the completion of the transaction, the insider owned 354,388 shares in the company, valued at approximately $2,533,874.20. The trade was a 2.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Evolus

Several large investors have recently modified their holdings of EOLS. Rice Hall James & Associates LLC increased its stake in Evolus by 17.4% during the 3rd quarter. Rice Hall James & Associates LLC now owns 1,168,886 shares of the company’s stock valued at $7,177,000 after purchasing an additional 172,846 shares in the last quarter. Frazier Life Sciences Management L.P. purchased a new stake in shares of Evolus during the second quarter valued at approximately $22,431,000. Frontier Capital Management Co. LLC increased its position in shares of Evolus by 37.9% during the second quarter. Frontier Capital Management Co. LLC now owns 1,664,828 shares of the company’s stock valued at $15,333,000 after acquiring an additional 457,533 shares in the last quarter. Campbell & CO Investment Adviser LLC purchased a new position in Evolus in the 2nd quarter worth approximately $434,000. Finally, Squarepoint Ops LLC lifted its position in Evolus by 830.2% in the 2nd quarter. Squarepoint Ops LLC now owns 105,797 shares of the company’s stock valued at $974,000 after acquiring an additional 94,423 shares in the last quarter. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Evolus News Summary

Here are the key news stories impacting Evolus this week:

• Positive Sentiment: Company issued FY‑2026 revenue guidance of $327M–$337M, above Street consensus (~$316M), signaling higher growth expectations for 2026 and supporting upside to sales forecasts. Evolus outlines 2026 revenue guidance
• Positive Sentiment: Company reported strong 2025 results (nearly $300M in total net revenue, sixth consecutive year of double‑digit growth) and said it expects sustainable profitability beginning in 2026 — a material shift in the story toward margin improvement. Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results
• Positive Sentiment: BTIG Research reaffirmed a “buy” rating and set a $13 price target — a substantial upside from recent levels that likely encouraged momentum trading and contributed to the rally. BTIG reaffirmed buy (Benzinga)
• Neutral Sentiment: Investors and analysts are parsing call/transcript details on product portfolio expansion and international rollouts; several transcripts and call highlights are available for deeper review. Earnings call highlights (Yahoo)
• Neutral Sentiment: Some outlets reported slightly different EPS metrics (adjusted vs. GAAP), e.g., Zacks noted an EPS in line with its estimate — this creates mixed headline reads but doesn’t change the top‑line/guidance narrative. Zacks: matches Q4 earnings estimates
• Negative Sentiment: There are mixed EPS headlines: some reports showed a miss on the quarterly EPS figure versus consensus (reported $0.00 vs. $0.09 estimate in one summary), which could temper enthusiasm if profitability metrics disappoint. Evolus earnings summary (MarketBeat)
• Negative Sentiment: Analyst models still show an overall negative EPS outlook for the current fiscal year in some consensus tallies, indicating profitability remains a forward risk if execution or margins slip. Earnings call transcript (Seeking Alpha)

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.